Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes

What are the most cost-effective management approaches for detecting, preventing, and treating metabolic dysfunction–associated steatohepatitis and liver fibrosis among people living with type 2 diabetes (T2D) in 12 countries?This economic evaluation found that the standard of care had the lowest average cost-effectiveness ratios in 8 countries; intensive lifestyle interventions (ILIs) after screening were cost-effective in all countries; and ILIs and semaglutide or resmetirom therapy were cost-effective in 11 and 7 countries, respectively.In this study, most proposed management approaches among people living with T2D were cost-effective in most countries.

Corresponding Author: Jeffrey V. Lazarus, PhD, CUNY Graduate School of Public Health and Health Policy, 55 W 125th St, New York, NY 10027 (jeffrey.lazarus@sph.cuny.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.